US EditionTrump announces chips, drug probes, opening door to tariffs
- President Donald Trump's administration is investigating U.S. Semiconductor and pharmaceutical imports, signaling potential tariffs on these sectors, according to filings with the Federal Register.
- The Department of Commerce initiated a Section 232 investigation into the national security risks of importing pharmaceuticals, which could pave the way for future tariffs.
- Trump stated that domesticating pharmaceutical production is vital for national security and highlighted the disparity in drug pricing between the U.S. And other countries, such as London.
- The investigation will examine the role of foreign supply chains in meeting U.S. Pharmaceutical needs, with public comments due by April 16, 2025, potentially expediting the process.
249 Articles
249 Articles
Tariffs: Why the threat of taxing semiconductors is "a dangerous game" for the global economy
Donald Trump has promised separate tariff measures on these essential components of the digital economy. At the risk of disrupting the supply chain and pushing US companies.
Trump Tariffs Roil Semiconductor Stocks, Test Loeb's Portfolio - Bloom Energy (NYSE:BE), Carpenter Tech (NYSE:CRS)
President Donald Trump established a new body within the Commerce Department to manage the CHIPS and Science Act of 2022, benefiting companies like Taiwan Semiconductor Manufacturing Co Ltd (NYSE:TSM). Here's a look at some of hedge fund manager Dan Loeb‘s semiconductor and electrical stocks year-to-date: NET Power Inc. (NYSE:NPWR) shares dropped 79.89%; its peer, Bloom Energy (NYSE:BE), saw a decline of 24.71% YTD. As of the fourth quarter of …
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
Coverage Details
Bias Distribution
- 56% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
